Literature DB >> 29782783

Posterior Reversible Encephalopathy Syndrome (PRES) Presenting as Status Epilepticus: A Case Report and Literature Review.

Prabin Sharma, Mohemmedd Khalid Abbas, Michael Huynh.   

Abstract

Posterior reversible encephalopathy syndrome (PRES) is one of many causes of status epilepticus (SE). Itis defined classically as a clinical radiographic entity, characterized by presentation of headache, altered mental status, visual disturbances, seizures, and typical neuroradiographic findings of symmetrical white-matter edema. Predisposing conditions include uncontrolled hypertension, eclampsia, and use of chemotherapeu- tic and immunosuppressant agents. Bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor (VEGF), is used in a combination with FOLFOX [FOL - Folinic acid; F - Fluorouracil (5-FU); OX - Oxaliplatin] as a first-line treatment for patients with metastatic colorectal cancer. We present a case of a 52-year-old male on systemic chemotherapy with FOLFOX and bevacizumab who presented with SE and was diagnosed with PRES. His symptoms resolved with intensive control of blood pressure and discontinuation of chemotherapy. Bevacizumab-induced vasospasm, endothelial and blood-brain-barrier dysfunction, in combination with elevated blood pressure, were likely the underlying mechanism of PRES in our patient.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 29782783

Source DB:  PubMed          Journal:  Conn Med        ISSN: 0010-6178


  1 in total

1.  PRES-like leukoencephalopathy presenting with status epilepticus associated with Brentuximab Vedotin treatment.

Authors:  Alessandro Orsini; Sayla Bernasconi; Maria Cristina Bianchi; Ilaria Trivelli; Maria Cristina Menconi; Margherita Nardi; Andrea Santangelo; Gabriella Casazza; Niccolò Carli; Maria Grazia Esposito; Diego Peroni; Pasquale Striano; Thomas Foiadelli; Alice Bonuccelli
Journal:  Acta Biomed       Date:  2022-03-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.